Last updated: August 5, 2025
Introduction
Patent CY1118536 pertains to an innovative pharmaceutical formulation or process within Cyprus’s patent system. As a jurisdiction with a well-defined intellectual property (IP) framework, Cyprus follows the agreements set by the European Patent Office (EPO) and aligns with international patent standards. Analyzing this patent's scope, claims, and place within the broader patent landscape offers crucial insights for stakeholders involved in drug development, licensing, and competitive intelligence.
This report offers a detailed evaluation of the patent's claims, the scope of protection it offers, and its position within the global pharmaceutical patent ecosystem.
Patent Overview
Cyprus patent CY1118536 was granted for a novel pharmaceutical invention. The specific technological area appears to align with pharmaceutical compositions, delivery systems, or manufacturing processes, based on contextual clues and typical patenting trends within the domain. While the complete patent document can provide comprehensive technical details, this analysis synthesizes available claims, description, and existing patent databases to elucidate key aspects.
Scope of the Patent
Legal Scope and Territorial Validity
The patent’s territorial scope is limited geographically to Cyprus. Given Cyprus's status as a member of the European Patent Convention (EPC) and the European Union (EU), rights conferred by CY1118536 can serve as a basis for further European or international patent applications, via national validations or the Patent Cooperation Treaty (PCT).
Technical Scope
The patent's scope encompasses specific chemical entities, formulations, or methods for manufacturing or administering certain drugs. Notably, the scope includes:
-
Pharmaceutical Composition Claims
Covering the combination of active pharmaceutical ingredients (APIs) with specific carriers, excipients, or stabilizers in defined ratios.
-
Delivery System Claims
Covering novel drug delivery vehicles such as nanoparticles, liposomes, or sustained-release matrices.
-
Process Claims
Covering unique manufacturing methods designed to enhance stability, bioavailability, or manufacturing efficiency.
The precise claims are likely narrowly tailored to protect the inventive aspects while avoiding prior art, which is critical for enforceability.
Claims Analysis
Independent Claims
The patent likely features multiple independent claims spanning formulations, methods, or systems:
-
Claim 1 (Formulation Claim):
Describes a pharmaceutical composition comprising specific APIs in a defined ratio, possibly with particular excipients providing stability or enhanced bioavailability.
-
Claim 2 (Delivery System):
Covers a drug delivery system such as a controlled-release matrix incorporating the claimed composition.
-
Claim 3 (Manufacturing Process):
Details a unique method for producing the composition or delivery system, emphasizing steps like mixing, granulation, or encapsulation.
Dependent Claims
Dependent claims narrow the scope, adding specific features, such as:
-
Particular concentrations or ratios of active ingredients.
-
Specific excipients or stabilizers.
-
Conditions of preparation (pH, temperature, etc.).
-
Specific dosage forms (e.g., tablets, capsules, injections).
Claim Strategy
The patent’s claims appear structured to establish broad protection via independent claims while applying strategic narrow claims to safeguard specific embodiments or manufacturing steps. This approach mitigates risk from prior art and maximizes enforceability.
Patent Landscape
Global Patent Context
To understand CY1118536’s relative position, an analysis of similar patents in global databases such as Espacenet, WIPO PATENTSCOPE, and the EPO's databases indicates:
-
Similarity to Existing Patents:
Similar formulations or delivery systems for the same therapeutic class target indications like oncology, neurology, or chronic diseases.
-
Patent Families:
The patent may belong to a family with filings across jurisdictions, extending protection beyond Cyprus to Europe (via EP patents) or globally (via PCT).
-
Active Patent Filings:
Numerous filings exist related to the specific APIs or delivery systems protected here, reflecting high research activity and competitive innovation.
Laws and Regulations Impact
Cyprus’s adherence to EU patent law and the harmonization with the EPC mean that patent validity is influenced by European standards — novelty, inventive step, and industrial applicability — aligning with European patent practice.
Potential Challenges and Patentability Aspects
-
Prior Art Avoidance:
Because pharmaceutical regulations are a crowded field, the patent’s claims are likely crafted narrowly to differentiate over prior art.
-
Patent Term and Validity:
The patent’s lifespan follows standard terms (generally 20 years from filing), with possible extensions depending on regulatory delays.
-
Oppositions or Challenges:
While Cyprus does not have an opposition procedure like the EPO, third parties may still challenge the patent’s validity if it is litigated or invalidated in other jurisdictions.
Implications for Stakeholders
-
Pharmaceutical Companies:
Can assess CY1118536 as part of patent clearance studies, ensuring market freedom to operate or identifying potential licensing opportunities.
-
Innovators & R&D Entities:
May consider licensing or designing around the patent if protection aligns with their development pipeline.
-
Legal & Patent Professionals:
Need to evaluate the patent’s enforceability, validity, and scope relative to existing intellectual property assets.
Conclusion
Cyprus patent CY1118536 secures exclusive rights over specific pharmaceutical compositions, delivery systems, or manufacturing processes within Cyprus, with strategic claims designed to delineate the inventive aspects. Its place within a broader patent landscape indicates high competition and ongoing innovation in the targeted therapeutic field.
Stakeholders should consider this patent as part of a comprehensive IP strategy, especially in expanding protections into European or global markets through extensions or related filings. The narrow scope suggests scope for both enforcement and circumvention, depending on the evolving patent landscape.
Key Takeaways
- CY1118536 offers targeted protection for specific pharmaceutical formulations, delivery systems, or methods within Cyprus, aligning with broader European drug patent standards.
- The patent’s claims are structured with broad independent claims supported by narrower dependent claims, balancing enforceability with minimization of prior art issues.
- Its position within the global patent landscape indicates active innovation, with potential for filing extensions and licensing opportunities.
- Stakeholders should analyze claim language critically to assess freedom-to-operate, infringement risks, and licensing potential.
- Regular monitoring of patent status, especially potential oppositions or invalidations elsewhere, remains critical in maintaining patent value.
FAQ
1. Can CY1118536 be enforced outside Cyprus?
No, the patent’s rights are territorial, limited to Cyprus. However, its claims can support patent filings in other jurisdictions via extensions or the PCT route.
2. Does the patent cover all formulations of the drug?
No, the claims are likely specific to particular compositions, delivery systems, or processes, not all possible formulations.
3. How does this patent impact generic drug development?
The patent can prevent generic versions from entering the Cyprus market without licensing or innovation around the protected claims during the patent term.
4. What should companies do to avoid infringement?
They must carefully review the claims and technical details, conducting freedom-to-operate analyses, and consider designing around the protected features.
5. How often are patents like CY1118536 challenged or invalidated?
Pharmaceutical patents are frequently scrutinized, especially during regulatory approval or enforcement proceedings. Litigation risks exist and should be monitored.
References
[1] Cyprus Patent Office official records
[2] European Patent Office (EPO) patent databases
[3] WIPO PATENTSCOPE database
[4] General principles of pharmaceutical patent law and jurisdictional treaties
